Baseline characteristics of patients with heart failure with
preserved ejection fraction in the EMPEROR-Preserved trial

J 2020

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

ANKER, S. D., J. BUTLER, G. FILIPPATOS, M. S. KHAN, J. P. FERREIRA et. al.

Basic information

Original name

Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial

Authors

ANKER, S. D. (guarantor), J. BUTLER, G. FILIPPATOS, M. S. KHAN, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, M. F. SERONDE, D. SIM, Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER

Edition

European Journal of heart Failure, Hoboken, Wiley, 2020, 1388-9842

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Slovenia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 15.534

RIV identification code

RIV/00216224:14110/20:00118193

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ejhf.2064

UT WoS

000615960600025

Keywords in English

Heart failure with preserved ejection fraction; Sodium glucose co transporter 2 inhibitors; Empagliflozin

Abstract

V originále

Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.

Citovat

ANKER, S. D., J. BUTLER, G. FILIPPATOS, M. S. KHAN, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, M. F. SERONDE, D. SIM, Jindřich ŠPINAR, I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. European Journal of heart Failure. Hoboken: Wiley, 2020, vol. 22, No 12, p. 2383-2392. ISSN 1388-9842. Available from: https://dx.doi.org/10.1002/ejhf.2064.

@article{1743517,
   author = {Anker, S. D. and Butler, J. and Filippatos, G. and Khan, M. S. and Ferreira, J. P. and Bocchi, E. and Bohm, M. and BrunnerandLa, Rocca H. P. and Choi, D. J. and Chopra, V. and Chuquiure, E. and Giannetti, N. and GomezandMesa, J. E. and Janssens, S. and Januzzi, J. L. and GonzalezandJuanatey, J. R. and Merkely, B. and Nicholls, S. J. and Perrone, S. V. and Pina, I. L. and Ponikowski, P. and Senni, M. and Seronde, M. F. and Sim, D. and Špinar, Jindřich and Squire, I. and Taddei, S. and Tsutsui, H. and Verma, S. and Vinereanu, D. and Zhang, J. and Jamal, W. and Schnaidt, S. and Schnee, J. M. and Brueckmann, M. and Pocock, S. J. and Zannad, F. and Packer, M.},
   article_location = {Hoboken},
   article_number = {12},
   doi = {http://dx.doi.org/10.1002/ejhf.2064},
   keywords = {Heart failure with preserved ejection fraction; Sodium glucose co transporter 2 inhibitors; Empagliflozin},
   language = {eng},
   issn = {1388-9842},
   journal = {European Journal of heart Failure},
   title = {Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial},
   url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2064},
   volume = {22},
   year = {2020}
}

TY  - JOUR
ID  - 1743517
AU  - Anker, S. D. - Butler, J. - Filippatos, G. - Khan, M. S. - Ferreira, J. P. - Bocchi, E. - Bohm, M. - Brunner-La, Rocca H. P. - Choi, D. J. - Chopra, V. - Chuquiure, E. - Giannetti, N. - Gomez-Mesa, J. E. - Janssens, S. - Januzzi, J. L. - Gonzalez-Juanatey, J. R. - Merkely, B. - Nicholls, S. J. - Perrone, S. V. - Pina, I. L. - Ponikowski, P. - Senni, M. - Seronde, M. F. - Sim, D. - Špinar, Jindřich - Squire, I. - Taddei, S. - Tsutsui, H. - Verma, S. - Vinereanu, D. - Zhang, J. - Jamal, W. - Schnaidt, S. - Schnee, J. M. - Brueckmann, M. - Pocock, S. J. - Zannad, F. - Packer, M.
PY  - 2020
TI  - Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
JF  - European Journal of heart Failure
VL  - 22
IS  - 12
SP  - 2383-2392
EP  - 2383-2392
PB  - Wiley
SN  - 13889842
KW  - Heart failure with preserved ejection fraction
KW  - Sodium glucose co transporter 2 inhibitors
KW  - Empagliflozin
UR  - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2064
L2  - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2064
N2  - Aims EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 +/- 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41-50%. The mean LVEF (54 +/- 9%) was slightly lower while the median NT-proBNP [974 (499-1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.
ER  -

ANKER, S. D., J. BUTLER, G. FILIPPATOS, M. S. KHAN, J. P. FERREIRA, E. BOCCHI, M. BOHM, Rocca H. P. BRUNNER-LA, D. J. CHOI, V. CHOPRA, E. CHUQUIURE, N. GIANNETTI, J. E. GOMEZ-MESA, S. JANSSENS, J. L. JANUZZI, J. R. GONZALEZ-JUANATEY, B. MERKELY, S. J. NICHOLLS, S. V. PERRONE, I. L. PINA, P. PONIKOWSKI, M. SENNI, M. F. SERONDE, D. SIM, Jindřich ŠPINAR, I. SQUIRE, S. TADDEI, H. TSUTSUI, S. VERMA, D. VINEREANU, J. ZHANG, W. JAMAL, S. SCHNAIDT, J. M. SCHNEE, M. BRUECKMANN, S. J. POCOCK, F. ZANNAD and M. PACKER. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. \textit{European Journal of heart Failure}. Hoboken: Wiley, 2020, vol.~22, No~12, p.~2383-2392. ISSN~1388-9842. Available from: https://dx.doi.org/10.1002/ejhf.2064.

Detailed Information on Publication Record